

Attorney Docket No.:

ABLE-0014

Inventors:

Ormerod and Winfield

Serial No.:

09/530,375

Filing Date:

July 7, 2000

Page 2



RECEIVED
JAN 04 2002
TECH CENTER 1600/2900

In the Claims:

Please cancel ~~claim~~ 27.

Please amend the claims as follows:

24. (amended) A topical formulation for the treatment of a dermatological condition which comprises a macrocyclic lactone antibiotic, an immunosuppressive macrolide wherein the macrolide is sirolimus, FK506 or SDZ ASM 981 and a permeation modulator which are present in relative amounts such that when a therapeutic amount is applied to the skin a minimal systemic effect is produced.

REMARKS

Claims 24-26 and 28-39 are pending in the instant application. Claims 24-39 have been rejected. Claim 27 has been canceled. Claim 24 has been amended. Reconsideration is respectfully requested in light of these amendments and the following remarks.

I. Rejection of Claims Under 35 U.S.C. 112, First Paragraph

Claims 24-39 have been rejected under 35 U.S.C. §112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to